
Advances in Experimental Medicine and Biology

Volume 1026

Editorial Board

IRUN R. COHEN, *The Weizmann Institute of Science, Rehovot, Israel*

ABEL LAJTHA, *N.S. Kline Institute for Psychiatric Research, Orangeburg,
NY, USA*

JOHN D. LAMBRIS, *University of Pennsylvania, Philadelphia, PA, USA*

RODOLFO PAOLETTI, *University of Milan, Milan, Italy*

NIMA REZAEI, *Children's Medical Center, Tehran University of Medical
Sciences, Tehran, Iran*

More information about this series at <http://www.springer.com/series/5584>

Erwei Song • Hai Hu
Editors

Translational Research in Breast Cancer

Biomarker Diagnosis, Targeted
Therapies and Approaches to
Precision Medicine

 Springer

Editors

Erwei Song
Sun Yat-sen Memorial Hospital
Sun Yat-sen University
Guangzhou, Guangdong, China

Hai Hu
Sun Yat-sen Memorial Hospital
Sun Yat-sen University
Guangzhou, Guangdong, China

ISSN 0065-2598 ISSN 2214-8019 (electronic)
Advances in Experimental Medicine and Biology
ISBN 978-981-10-6019-9 ISBN 978-981-10-6020-5 (eBook)
<https://doi.org/10.1007/978-981-10-6020-5>

Library of Congress Control Number: 2017959644

© Springer Nature Singapore Pte Ltd. 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by Springer Nature

The registered company is Springer Nature Singapore Pte Ltd.

The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

Preface

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths worldwide. Breast cancers are genetically heterogeneous, which can be generally classified into four categories with distinct patterns of molecular profile and different treatment strategies. Besides, about 5–10% of cases are inherited mainly due to the germline mutations of BRCA1 and BRCA2, which are key DNA repair regulators, and thus lead to the DNA repair-targeting therapy with PARP inhibitors. Unraveling the biological heterogeneity of breast cancer in its natural history and its responsiveness to therapy from one patient to another will help to translate new approaches for breast cancer prevention and treatment and improve the quality of care offered to breast cancer patients.

There is a broad consensus that cancer is a genetic disease and that accumulation of molecular alterations in the genome of somatic cells is the basis of cancer progression. In breast cancer, the accumulated mutations often result in the amplification of growth signal followed by the activation of PI3K/AKT/mTOR pathway and RAS/MEK/ERK pathway and thus cause the agitation of downstream transcription, metabolic reprogramming, etc., leading to the increase of breast cancer stem cell self-renewal and acceleration of cell cycle or less apoptosis. The understanding of genomic changes and oncogenic signaling cascade of breast cancer has inspired the development of targeting treatments, such as the clinical trials in PI3K, AKT, and mTORC1 inhibitors.

On the other hand, breast cancer, like other cancers, occurs because of an interaction between an environmental (external) factor and the genetically susceptible host. The immuno-environment has been demonstrated as a barrier of the clinical cancer. Overcoming the restriction of immune checkpoints is an essential step for cancer development. Therefore, recovering these checkpoints may prevent cancer progression. In addition, stromal cells such as tumor-associated macrophages (TAMs) promote tumorigenesis by limiting immuno-response or directly promoting cancer metastasis. The knowledge has been translated into successful approaches of immuno-therapies such as the application of anti-PD1 and anti-PDL1 strategies for malignancy treatment.

Together, elucidating the molecular landscape of breast cancers has facilitated the development of diagnostic, prognostic, and predictive biomarkers for clinical oncology. In addition, a burst of knowledge in cancer biology, immunology, genomics, metabolism, and so on has broken new grounds for designing innovative therapeutic approaches and selecting appropriate treatments according to the precise information of an individual cancer patient. The present book is an endeavor to convey a comprehensive knowledge of the translational efforts in breast cancer and address the latest approaches of precision medicine based on the understanding of breast cancer.

Contents

1	The Dawning of Translational Breast Cancer: From Bench to Bedside.	1
	Xueman Chen, Siting Fan, and Erwei Song	
2	Biomarker Studies in Early Detection and Prognosis of Breast Cancer.	27
	Gang Li, Jing Hu, and Guohong Hu	
3	The Preventive Intervention of Hereditary Breast Cancer	41
	Ayong Cao, Liang Huang, and Zhimin Shao	
4	Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.	59
	Kyung-Hee Chun, Jong Hoon Park, and Siting Fan	
5	Studies on DNA Damage Repair and Precision Radiotherapy for Breast Cancer	105
	Yanhui Jiang, Yimin Liu, and Hai Hu	
6	Targeted Therapies Against Growth Factor Signaling in Breast Cancer.	125
	Juan Du, Yu Yu, Jun Zhan, and Hongquan Zhang	
7	Targeting Stemness: Implications for Precision Medicine in Breast Cancer.	147
	Zhi-Mei Liang, Yang Chen, and Man-Li Luo	
8	Disrupting Tumor Angiogenesis and “the Hunger Games” for Breast Cancer	171
	Ziwei Zhou, Herui Yao, and Hai Hu	
9	Key Factors in Breast Cancer Dissemination and Establishment at the Bone: Past, Present and Future Perspectives	197
	Sioned Owen, Catherine Zabkiewicz, Lin Ye, Andrew J. Sanders, Chang Gong, and Wen G. Jiang	

10	Perspectives of Reprogramming Breast Cancer Metabolism	217
	Yi-Ping Wang and Qun-Ying Lei	
11	Metabolic Changes During Cancer Cachexia Pathogenesis	233
	Ng Shyh-Chang	
12	Cell Cycle Regulation in Treatment of Breast Cancer	251
	Zijie Cai and Qiang Liu	
13	BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer	271
	Hitomi Sumiyoshi Okuma and Kan Yonemori	
14	Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer	287
	Sumin Oh, Je Yeong Ko, Chaeun Oh, and Kyung Hyun Yoo	
15	Progress in Vaccine Therapies for Breast Cancer	315
	Xiaoyu Li and Xia Bu	
16	Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer	331
	Liyan Lao, Siting Fan, and Erwei Song	
17	New Approaches in CAR-T Cell Immunotherapy for Breast Cancer	371
	Jinghua Wang and Penghui Zhou	
18	Immune Checkpoint Blockade in Breast Cancer Therapy	383
	Xia Bu, Yihui Yao, and Xiaoyu Li	
19	Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer	403
	Hope S. Rugo, Huiping Li, and Xinyu Gui	